CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Phreesia (PHR) Investors of Securities Class Action Lawsuit Deadline on July 13, 2026

NEW YORK--(BUSINESS WIRE)--Jul 13, 2026--

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Phreesia, Inc. (“Phreesia” or the “Company”) (NYSE: PHR) and reminds investors of the July 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713811285/en/

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: Phreesia’s ability to capitalize on its growth potential through continued expansion of its Network Solutions segment, as well as contributions from its AccessOne acquisition. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Phreesia’s slowing demand and reduced visibility in key revenue streams, notably, the weakened pharmaceutical marketing commitments in its Network Solutions segment. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Phreesia’s securities at artificially inflated prices

After the market closed on March 30, 2026, Phreesia announced significantly reduced revenue growth projections for fiscal year 2027 guidance. The Company attributed the shortfall against its prior guidance to a combination of macroeconomic factors including “worsening visibility” and weaker pharmaceutical marketing commitments within its Network Solutions segment.

Investors and analysts reacted immediately to Phreesia’s revelation. The price of Phreesia’s common stock declined from a closing market price of $11.41 per share on March 30, 2025, to $8.38 per share on March 31, 2026, a decline of about 27%.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Phreesia’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Phreesia class action, go to www.faruqilaw.com/PHR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the Phreesia, Inc. Securities Class Action Lawsuit:

What is the Phreesia securities fraud lawsuit about?
The Phreesia securities fraud lawsuit is a federal securities class action alleging that Phreesia, Inc. (NYSE: PHR) and its executives made false and misleading statements to investors by overstating the Company's ability to capitalize on growth opportunities through its Network Solutions segment and its AccessOne acquisition, while concealing slowing demand, reduced visibility in key revenue streams, and weakening pharmaceutical marketing commitments. As the truth emerged on March 30, 2026 — when Phreesia announced significantly reduced revenue growth projections for fiscal year 2027 guidance, attributing the shortfall to "worsening visibility" and weaker pharmaceutical marketing commitments within its Network Solutions segment — PHR's stock price fell approximately 27%, from $11.41 to $8.38 per share, causing significant losses for investors.

Who may be eligible to participate in the Phreesia class action lawsuit?
Investors who purchased or acquired Phreesia, Inc. (PHR) stock between May 8, 2025 and March 30, 2026 — the Class Period — and suffered financial losses may be eligible to participate in the Phreesia securities class action. Participation as a class member does not require taking any affirmative legal action; eligible investors may recover losses simply by remaining members of the class. Whistleblowers, former Phreesia employees, and others with relevant information about the Company's conduct are also encouraged to come forward.

What is a lead plaintiff, and how can I seek appointment in the Phreesia lawsuit?
A lead plaintiff in the Phreesia class action is a court-appointed investor — typically the one with the largest financial interest in the case — who directs and oversees the litigation on behalf of all class members. Any Phreesia investor who purchased PHR stock during the Class Period may move the Court to serve as lead plaintiff through counsel of their choice. The deadline to seek lead plaintiff appointment is July 13, 2026. Importantly, choosing not to seek the lead plaintiff role does not affect an investor's ability to share in any recovery obtained for the class.

What should investors do if they purchased Phreesia stock during the Class Period?
Investors who purchased Phreesia, Inc. (PHR) stock between May 8, 2025 and March 30, 2026 and suffered losses should contact Faruqi & Faruqi, LLP immediately to discuss their legal rights. The deadline to seek appointment as lead plaintiff in the Phreesia securities class action is July 13, 2026. To speak directly with securities litigation partner Josh Wilson, call 877-247-4292 or 212-983-9330 (Ext. 1310), or visit www.faruqilaw.com/PHR for more information.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Phreesia (PHR) Investors of Securities Class Action Lawsuit Deadline on July 13, 2026

BUNIA, Congo (AP) — Dozens of people working at an Ebola treatment center in northeast Congo went on strike Monday over unpaid salaries and bonuses.

The striking staff at Rwampara General Hospital in Ituri province includes epidemiologists, case investigators, drivers and gravediggers who say they have not been paid by the Congolese authorities.

The hospital was shuttered by protesting staff, who blocked the road leading to the medical facility.

Some of the center's health workers and those working on the ground began striking last week, accusing authorities of failing to pay their wages since the outbreak began in May.

“We don’t know how it is possible to not have been paid for two months,” Bahati Claude, a health worker in the Rwampara health zone, told The Associated Press. “We don’t want to give up the job.”

The Congolese authorities declared a new Ebola outbreak on May 15, after the disease had been transmitting for weeks without official detection, according to the World Health Organization. The latest outbreak is caused by the rare Bundibugyo virus, which has no approved vaccine or treatment.

During a visit to Ituri last week, the Congolese health minister, Roger Kamba, said the government is verifying a list of those working to control the outbreak as some unrelated names have been added to the payroll.

“We must ensure that these payments reach the right people,” Kamba said. “We have faced a few challenges, notably changes to the lists, which have led to complaints from people saying they are not being paid even though they are working. We have the means to sort this out.”

There are 1,926 confirmed cases so far in the country, including 702 deaths, according to Congolese authorities.

Meanwhile, the World Health Organization Director-General Tedros Adhanom Ghebreyesus posted Monday on X that a second U.S. citizen, who is a humanitarian worker in eastern Congo, who contracted Ebola was transferred to Germany. The first American to test positive for the virus was a doctor working in Congo during the early weeks of the outbreak.

Last week, the Africa Centres for Disease Control and Prevention said that the outbreak is the fastest-growing Ebola outbreak ever recorded on the continent.

FILE - A health worker prepares a patient's blood sample for testing at Bunia General Hospital in Bunia, Congo, Thursday, June 11, 2026. (AP Photo/Moses Sawasawa, File)